Today, more than 90% of new drugs fail clinical trials in the US, and those that do succeed can take upwards of seven years to reach FDA approval.
Healthcare CEOs in the US are “trying to set course in an otherwise unpredictable, highly uncertain world,” according to this episode’s guest, Marshall Smith, global head of Goldman Sachs’ healthcare investment banking.
Exploring one of the highest growth sectors in China: healthcare.
The drivers behind healthcare’s explosive growth in China and how investors are viewing the industry’s risk and reward.
Ongoing public scrutiny of US drug prices has begun to limit the pricing power pharmaceutical companies have enjoyed for decades.
Macroeconomic pressures have hit the R&D returns of life sciences firms.